Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 13, 2014 - Issue 4
Submit an article Journal homepage
553
Views
9
CrossRef citations to date
0
Altmetric
Drug Safety Evaluations

Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies

Sergio BracardaOspedale San Donato, Medical Oncology, Arezzo, 52100, [email protected]
,
Daniel CastellanoHospital Universitario 12 de Octubre, Madrid, Spain
,
Giuseppe ProcopioFondazione IRCCS Istituto Nazionale dei Tumori, S.C. Medicina Oncologica 1, Via G.Venezian 1, Milano, 20133, Italy
,
Juan M SepúlvedaHospital Universitario 12 de Octubre, Madrid, Spain
,
Michele SisaniOspedale San Donato, Medical Oncology, Arezzo, 52100, [email protected]
,
Elena VerzoniFondazione IRCCS Istituto Nazionale dei Tumori, S.C. Medicina Oncologica 1, Via G.Venezian 1, Milano, 20133, Italy
&
Manuela SchmidingerMedizinische Universität Wien, Klinik für Innere Medizin I, Waehringer Guertel 18-20, Wien, A-1090, Austria
 show all
Pages 497-510 | Published online: 18 Mar 2014

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Vivek Narayan & Naomi Balzer Haas. (2016) Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. International Journal of Nephrology and Renovascular Disease 9, pages 65-72.
Read now

Articles from other publishers (8)

Kashif Haider, Shivani Sharma, Yuba Raj Pokharel, Subham Das, Alex Joseph, Abul Kalam Najmi, Faiz Ahmad & Mohammad Shahar Yar. (2022) Synthesis, biological evaluation, and in silico studies of indole‐tethered pyrazoline derivatives as anticancer agents targeting topoisomerase IIα. Drug Development Research 83:7, pages 1555-1577.
Crossref
Bieke Van der Veken, Guido R.Y. De Meyer & Wim Martinet. (2018) Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vascular Pharmacology 100, pages 34-40.
Crossref
Senji Hoshi, Kenji Numahata, Hidenori Kanno, Masahiko Sato, Akihito Kuromoto, Kunihisa Nezu, Takanari Sakai, Chihito Konno, Yuichi Ishizuka, Hideaki Izumi, Katsuyuki Taguchi, Kunio Ono, Kiyotsugu Hoshi, Satoshi Kanto, Rika Takahashi, Bilim Vladimir, Naoe Akimoto, Isoji Sasagawa & Shoichiro Ohta. (2017) Updated recommendation on molecular-targeted therapy for metastatic renal cell cancer. Molecular and Clinical Oncology 7:4, pages 591-594.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 395 414 .
M S Zabriskie, C A Eide, D Yan, N A Vellore, A D Pomicter, S L Savage, B J Druker, M W Deininger & T O'Hare. (2015) Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia 30:6, pages 1418-1421.
Crossref
Chiara Ciccarese, Alessandra Modena, Giampaolo Tortora & Francesco Massari. (2015) Kidney cancer and 2014: is innovation really over?. Future Oncology 11:9, pages 1437-1449.
Crossref
Tea Pemovska, Eric Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter Wells, Ciarán N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo Porkka, Brion W. Murray & Krister Wennerberg. (2015) Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519:7541, pages 102-105.
Crossref
Gilda G. Hillman, Fulvio Lonardo, David J. Hoogstra, Joseph Rakowski, Christopher K. Yunker, Michael C. Joiner, Gregory Dyson, Shirish Gadgeel & Vinita Singh-Gupta. (2014) Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors. Translational Oncology 7:3, pages 400-409.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.